eleva GmbH
03.05.2023 - 10:30
Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic ...
To the press release of eleva GmbH12.10.2021 - 10:30
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally ...
To the press release of eleva GmbH14.09.2021 - 10:30
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more ...
To the press release of eleva GmbH06.01.2021 - 10:00
Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further ...
To the press release of eleva GmbH03.06.2020 - 10:00
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the ...
To the press release of eleva GmbH 
